New Phase 3 trial: Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children — Hoffmann-La Roche
Why now
Thesis: Franchise life-extension, no immediate earnings effect
Catalyst to watch: Interim safety and immunogenicity results
Main risk: Pediatric immunogenicity or dosing setbacks
Why it matters
Pediatric hemophilia A prophylaxis trial for Roche's NXT007 could broaden a high-price biologic franchise if it succeeds.
Details
Sponsor: Hoffmann-La Roche; Status: Not Yet Recruiting; Conditions: Hemophilia A; Interventions: NXT007; Enrollment: 50 (estimated); First posted: 2026-09-24; NCT: NCT07838194
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-24 12:00 UTC